Table 3 Summary of on-therapy adverse events occurring in ≥10% of patients in either of the treatment arms (Chinese safety population)
Adverse event | Pazopanib N = 109 n (%) | Sunitinib N = 100 n (%) |
|---|---|---|
Patients with any event | 108 (> 99) | 99 (99) |
Hypertension | 65 (60) | 50 (50) |
Diarrhea | 57 (52) | 37 (37) |
Palmar-plantar erythrodysesthesia syndrome (HFS) | 52 (48) | 57 (57) |
Hair color changes | 47 (43) | 13 (13) |
Alanine aminotransferase increased | 45 (41) | 32 (32) |
Fatigue | 43 (39) | 41 (41) |
Aspartate aminotransferase increased | 41 (38) | 32 (32) |
Decreased appetite | 41 (38) | 32 (32) |
Proteinuria | 39 (36) | 39 (39) |
Leukopenia | 33 (30) | 43 (43) |
Blood bilirubin increased | 27 (25) | 21 (21) |
Neutropenia | 26 (24) | 36 (36) |
Neutrophil count decreased | 25 (23) | 40 (40) |
Platelet count decreased | 23 (21) | 39 (39) |
Blood creatinine increased | 21 (19) | 32 (32) |
Thrombocytopenia | 20 (18) | 39 (39) |
Nausea | 19 (17) | 15 (15) |
Vomiting | 19 (17) | 9 (9) |
Hypothyroidism | 18 (17) | 23 (23) |
Mouth ulceration | 17 (16) | 25 (25) |
White blood cell count decreased | 17 (16) | 33 (33) |
Eyelid edema | 16 (15) | 28 (28) |
Abdominal pain upper | 15 (14) | 7 (7) |
Bilirubin conjugated increased | 15 (14) | 6 (6) |
Blood bilirubin unconjugated increased | 15 (14) | 8 (8) |
Hemoglobin decreased | 13 (12) | 31 (31) |
Skin hypopigmentation | 13 (12) | 3 (3) |
Blood triglycerides increased | 12 (11) | 14 (14) |
Blood lactate dehydrogenase increased | 9 (8) | 18 (18) |
Epistaxis | 9 (8) | 11 (11) |
Hypogeusia | 9 (8) | 12 (12) |
Pain in extremity | 9 (8) | 12 (12) |
Rash | 9 (8) | 14 (14) |
Blood thyroid stimulating hormone increased | 8 (7) | 19 (19) |
Anemia | 7 (6) | 25 (25) |
Dysgeusia | 6 (6) | 12 (12) |
Peripheral edema | 6 (6) | 14 (14) |
Blood cholesterol increased | 5 (5) | 10 (10) |
Stomatitis | 4 (4) | 12 (12) |
Facial edema | 3 (3) | 17 (17) |
Yellow skin | 3 (3) | 22 (22) |
Nasopharyngitis | 2 (2) | 10 (10) |
Xanthochromia | 1 (< 1) | 10 (10) |